[Comparative safety study of two commercialised vaccines against canine babesiosis induced by Babesia canis].

Abstract

The safety of two vaccines available on the French market against canine babesiosis - Nobivac Piro® (NP) and Pirodog® (P) - have been evaluated. Their local, general and biochemical impacts have been compared in a controlled experimental study. Three groups were used: a control group (T) and two groups vaccinated twice at 21 days interval. All dogs presented moderate local reaction. However, either clinical and biological parameters showed that the NP group presented a significantly more intense reaction at the injection site compared to the P group. No statistical difference has been revealed between the groups P and T evolutions.

• Authors: L Freyburger, L Lemaitre, C Médaille, F Oberli, L Fanchon, P Bergamo
• Journal: Parasite (Paris, France) (Parasite) Vol. 18 Issue 4 Pg. 311-8 (Nov 2011) ISSN: 1252-607X [Print] France
• Vernacular Title: Etude comparative de l'innocuité de deux vaccins commerciaux contre la babésiose canine provoquée par Babesia canis.
• PMID: 22091461 (Publication Type: Comparative Study, English Abstract, Journal Article)

Chemical References

• Protozoan Vaccines
• C-Reactive Protein

Topics

• Animals
• Babesia (immunology)
• Babesiosis (prevention & control, veterinary)
• Blood Sedimentation
• Body Temperature
• C-Reactive Protein (analysis)
• Dog Diseases (prevention & control)
• Dogs
• Immunization, Secondary (veterinary)
• Male
• Protozoan Vaccines (standards, toxicity)
• Safety